A detailed history of Ubs Group Ag transactions in Pro Phase Labs, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 10,508 shares of PRPH stock, worth $8,091. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,508
Holding current value
$8,091
% of portfolio
0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.16 - $4.06 $22,697 - $42,662
10,508 New
10,508 $25,000
Q1 2024

May 13, 2024

BUY
$4.47 - $6.47 $14,853 - $21,499
3,323 New
3,323 $21,000
Q1 2023

May 12, 2023

SELL
$6.62 - $9.57 $78,069 - $112,859
-11,793 Reduced 71.3%
4,748 $36,000
Q4 2022

Feb 08, 2023

SELL
$8.78 - $12.47 $78,317 - $111,232
-8,920 Reduced 35.03%
16,541 $159,000
Q3 2022

Nov 10, 2022

BUY
$8.96 - $14.7 $215,255 - $353,152
24,024 Added 1671.82%
25,461 $287,000
Q2 2022

Aug 10, 2022

SELL
$6.52 - $13.24 $436 - $887
-67 Reduced 4.45%
1,437 $18,000
Q1 2022

May 16, 2022

SELL
$6.2 - $7.87 $2,256 - $2,864
-364 Reduced 19.49%
1,504 $11,000
Q4 2021

Feb 14, 2022

BUY
$5.13 - $7.89 $9,582 - $14,738
1,868 New
1,868 $13,000
Q3 2021

Nov 15, 2021

SELL
$4.89 - $7.82 $44,205 - $70,692
-9,040 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$4.61 - $6.83 $40,863 - $60,541
8,864 Added 5036.36%
9,040 $56,000
Q1 2021

May 12, 2021

SELL
$6.19 - $16.0 $5,849 - $15,120
-945 Reduced 84.3%
176 $1,000
Q4 2020

Feb 11, 2021

SELL
$3.9 - $11.25 $15,529 - $44,797
-3,982 Reduced 78.03%
1,121 $11,000
Q3 2020

Nov 12, 2020

SELL
$1.4 - $3.87 $2,550 - $7,051
-1,822 Reduced 26.31%
5,103 $18,000
Q2 2020

Jul 31, 2020

SELL
$1.2 - $1.99 $9,166 - $15,201
-7,639 Reduced 52.45%
6,925 $10,000
Q1 2020

May 01, 2020

BUY
$1.74 - $2.1 $1,900 - $2,293
1,092 Added 8.11%
14,564 $28,000
Q4 2019

Feb 14, 2020

BUY
$1.66 - $2.2 $224 - $297
135 Added 1.01%
13,472 $26,000
Q3 2019

Nov 14, 2019

SELL
$1.63 - $2.2 $5,766 - $7,783
-3,538 Reduced 20.97%
13,337 $26,000
Q2 2019

Aug 14, 2019

SELL
$2.1 - $3.07 $5,298 - $7,745
-2,523 Reduced 13.01%
16,875 $36,000
Q1 2019

May 14, 2019

SELL
$2.7 - $3.65 $8,756 - $11,836
-3,243 Reduced 14.32%
19,398 $58,000
Q4 2018

Feb 14, 2019

SELL
$2.95 - $3.27 $1,935 - $2,145
-656 Reduced 2.82%
22,641 $71,000
Q3 2018

Nov 14, 2018

SELL
$2.94 - $3.23 $7,103 - $7,803
-2,416 Reduced 9.4%
23,297 $70,000
Q2 2018

Aug 14, 2018

BUY
$2.84 - $5.41 $24,500 - $46,672
8,627 Added 50.49%
25,713 $84,000
Q1 2018

May 15, 2018

SELL
$2.24 - $3.21 $31 - $44
-14 Reduced 0.08%
17,086 $51,000
Q4 2017

Feb 14, 2018

SELL
$2.05 - $2.3 $10,239 - $11,488
-4,995 Reduced 22.61%
17,100 $37,000
Q3 2017

Nov 14, 2017

BUY
$2.03 - $2.29 $22,269 - $25,121
10,970 Added 98.61%
22,095 $48,000
Q2 2017

Aug 14, 2017

BUY
N/A
525 Added 4.95%
11,125 $23,000
Q1 2017

Nov 14, 2017

BUY
N/A
10,600
10,600 $24,000

Others Institutions Holding PRPH

About ProPhase Labs, Inc.


  • Ticker PRPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 16,024,400
  • Market Cap $12.3M
  • Description
  • ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Lege...
More about PRPH
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.